Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 19, 2014 ... ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the addition ... 2014-2018" report to their offering. ... involves the study of chromosomes using molecular ... of genes and chromosomes. It plays a ...
(Date:9/18/2014)...  Low T Center endorses the recommendations of ... Hyattsville, Maryland earlier this week. The FDA ... population for testosterone therapy (TRT), as well as ... recent claims from studies that TRT affects cardiovascular ... do not provide convincing evidence that TRT is ...
(Date:9/18/2014)... KANSAS CITY, Kan. , Sept. 18, 2014 ... ), a pet therapeutics company focused on licensing, ... animals, today announced the full exercise of the ... common stock in connection with the company,s previously ... stock.  All of the shares are being offered ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... VIEW, Calif., Dec. 21, 2010 MAP Pharmaceuticals, Inc. (Nasdaq: ... ™ open-label safety trial.  The Company has now completed ... (NDA) for LEVADEX and plans to submit an NDA in ... inhaled migraine therapy that has completed Phase 3 clinical development ...
... -- China Botanic Pharmaceutical Inc. (AMEX: CBP ... and distributor of botanical products, bio-pharmaceuticals and traditional Chinese ... considerable progress in its efforts to comply with the ... 404") for fiscal year 2010. As announced ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 2MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 3China Botanic Announces Progress on its SOX 404 Compliance Program 2China Botanic Announces Progress on its SOX 404 Compliance Program 3
(Date:9/19/2014)... September 19, 2014 September 1, 2014 ... will introduce its state-of-the-art, fiber based, Smart Private Network ... implementation begins in Tahlequah, Oklahoma, which is the capital ... connecting facilities within the Tahlequah area for the remainder ... educational institutions within the fourteen counties of the Cherokee ...
(Date:9/19/2014)... 19, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Potassium Chloride . , ... recalled one lot of Potassium Chloride Injection 10mEq ... cartons. Potassium Chloride, administered intravenously, is used to treat potassium ... on a labeling error on the shipping cartons in a ...
(Date:9/19/2014)... 2014 Mount Pleasant Retirement Village ... Health and Well-Being Coach Christi Hall to campus. , Hall’s ... brain tumors and gaining weight as a result of years ... and learning about nutrition. One year later she had lost ... her strength, endurance and cardio. , After joining the YMCA ...
(Date:9/19/2014)... Final Cut Pro X plugin and effects manufacturer, ... template for Apple's Final Cut Pro X . , ... FCPX users to create a professional themed video with ease ... Pixel Film Studios, "With 48 camera options and On-Screen controls, ... Theme." , Float features all of the tools needed ...
(Date:9/19/2014)... Washington, D.C. (PRWEB) September 19, 2014 ... in Madison County Circuit Court (case 14-L-1175), following a ... Carole Owen is suing DePuy Orthopaedics Inc. and ... product was defective. Flood Law Group, a nationally known ... and has been following developments in litigation involving defective ...
Breaking Medicine News(10 mins):Health News:The Cherokee Nation and RBSC sign a “Memorandum of Agreement” That Brings Smart Connect to the Cherokee Nation 2Health News:Baxter Recalls Potassium Chloride Injection: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Pixel Film Studios Releases Float Theme for Final Cut Pro X Users 2Health News:Flood Law Group Comments on Recent Hip Replacement Lawsuit 2
... released today by the Association for Psychological Science: , , ... 65; in 2000 that number had jumped to 12.6 percent; and ... in that category. , , Cognitive decline was long ... seen a surge of interest in activities and products touted to ...
... Arcadia Resources, Inc. (NYSE Amex: KAD ... and pharmacy services under the Arcadia HealthCare(SM) brand, has ... Co., as Vice President of DailyMed(TM) Pharmacy Operations , ... the Indianapolis pharmacy operations, manage system integration within DailyMed ...
... Region recognizes immediate, ... ... Center and CHRISTUS St. Vincent Medical Group in Santa Fe, New Mexico, through teamwork, focused ... in nine months. CHRISTUS Health began managing CHRISTUS St. Vincent in April 2008 and ...
... health communications company StayWell Custom Communications (SCC), a division ... Grocer magazine to publish the white paper ... the Economy" to spotlight the retail sector,s growing need ... , , The white paper is a ...
... to include " Oncology Therapeutic ... , , - Center will train pharmacists to specialize in ... 23 Medco Health Solutions, Inc. (NYSE: MHS ), joined ... at AllPoints at Anson will house the Medco Therapeutic Resource Center(R) ...
... diagnostics market is poised for expansion with segments such ... potential. Heightened efforts to generate awareness about diabetes and ... development. For instance, limited awareness about HbA1C tests is ... curtailed with more education about the test. , ...
Cached Medicine News:Health News:Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age 2Health News:Major New Report Establishes Effective Methods of Enhancing and Preserving Brain Power as We Age 3Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 2Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 3Health News:Arcadia HealthCare Names Former Walgreen's Executive Charles Goodall as Vice President of DailyMed(TM) Pharmacy Operations 4Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 2Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 3Health News:Pivotal White Paper Examines Retail Industry's Critical Role in Reengineering the Health Care System 2Health News:Pivotal White Paper Examines Retail Industry's Critical Role in Reengineering the Health Care System 3Health News:Medco's Advanced Pharmacy Adds 162 New Jobs for Total of 1,400 2Health News:Medco's Advanced Pharmacy Adds 162 New Jobs for Total of 1,400 3Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 2Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: